#238Extended selection 101–300

Fusion Pharmaceuticals

Canada · Canada

Oncology / ADC / high-potencyRadiopharmaceuticals

Manufacturing profile

Oncology / ADC / high-potency
Radiopharmaceuticals

Country: Canada

Macro-region: Canada

Selection basis

The company is placed in positions 101–300 as a manufacturer, biotech, specialty-pharma, generics or CDMO company with practical relevance to the existing FUZKK catalog.

The Top 300 is a FUZKK atlas priority rather than a single official revenue table. China, India, Israel, the USA and the European scope are excluded because separate atlases already cover them.

Representative manufacturing and QC chain

  1. 1Contained dispensing and high-potency handling
  2. 2Chemical synthesis or biologic upstream
  3. 3Purification and formulation
  4. 4HPLC/LC-MS/CE and potency analytics
  5. 5Controlled fill-finish, cleaning and release evidence
  6. 6Radionuclide production or isotope sourcing
  7. 7Shielded synthesis and hot-cell operations
  8. 8Sterile filtration and aseptic dispensing
  9. 9Activity, identity and radionuclidic/radiochemical purity

Relevant FUZKK packages

Lumex — instrumental QC

Suggested first pilot

  1. Confirm one real product, method or recurring QC review.
  2. Record the instrument, export format and current specification.
  3. Select 3–7 utilities from the map above.
  4. Run a PASS/FAIL sample and agree the expected output.
  5. After user validation, expand to other products and sites.

Mapping boundary

The Top 300 is a FUZKK atlas priority rather than a single official revenue table. China, India, Israel, the USA and the European scope are excluded because separate atlases already cover them.

Methodology